Department of Neurology, Taizhou Second People's Hospital, China.
Ankang Ward, Taizhou Second People's Hospital, China.
FEBS J. 2021 Jan;288(1):212-228. doi: 10.1111/febs.15325. Epub 2020 Jul 15.
Malignant gliomas are a heterogeneous group of brain tumors with a poor prognosis, which is largely due to its aggressive invasiveness and angiogenesis. In recent years, it has been found that multiple long noncoding RNAs (lncRNAs) participate in a wide range of biological functions including angiogenesis through the regulation of gene expression in cancers. In this study, we investigate and report the novel role of lncRNA SLC26A4-AS1 in gliomas, with a novel mechanism involving transcription factors NFKB1 and NPTX1. We determined that SLC26A4-AS1 was downregulated in human glioma tissues and cells. Furthermore, overexpression of SLC26A4-AS1 or NPTX1 restrained the aggressiveness of glioma cells and their pro-angiogenic ability. SLC26A4-AS1 was also found to upregulate NPTX1 by recruiting NFKB1 into the NPTX1 promoter. Moreover, silencing of either NPTX1 or NFKB1 restored the aggressive and pro-angiogenic properties of glioma cells in the presence of SLC26A4-AS1. Taken together, we demonstrate that SLC26A4-AS1 promotes NPTX1 transcriptional activity by recruiting NFKB1 and thus exerting antiangiogenic effects on glioma cells. This study provides an experimental basis for the intervention of SLC26A4-AS1 in the treatment of gliomas.
恶性神经胶质瘤是一组预后不良的异质性脑肿瘤,这主要是由于其侵袭性和血管生成。近年来,人们发现多种长链非编码 RNA(lncRNA)通过调节癌症中的基因表达,参与广泛的生物学功能,包括血管生成。在本研究中,我们研究并报告了 lncRNA SLC26A4-AS1 在神经胶质瘤中的新作用,其涉及转录因子 NFKB1 和 NPTX1 的新机制。我们确定 SLC26A4-AS1 在人神经胶质瘤组织和细胞中下调。此外,SLC26A4-AS1 或 NPTX1 的过表达抑制了神经胶质瘤细胞的侵袭性及其促血管生成能力。还发现 SLC26A4-AS1 通过将 NFKB1 募集到 NPTX1 启动子上来上调 NPTX1。此外,在存在 SLC26A4-AS1 的情况下,沉默 NPTX1 或 NFKB1 恢复了神经胶质瘤细胞的侵袭性和促血管生成特性。总之,我们证明 SLC26A4-AS1 通过募集 NFKB1 促进 NPTX1 的转录活性,从而对神经胶质瘤细胞发挥抗血管生成作用。这项研究为干预 SLC26A4-AS1 在神经胶质瘤治疗中的作用提供了实验依据。